News

These represent key steps toward achieving the company’s vision to commercialize compounds it has developed to prevent certain types of hearing loss. The company’s product will be the

Non-24 is a serious chronic circadian rhythm disorder that affects up to 70 percent of people who are totally blind. The company has launched HETLIOZSolutions to support and

Starting syringe work earlier, in full or partial parallel with vial development, can cut up to 18 months off time-to-market. Vetter’s self-contained, modular packages are designed to provide

Founded in April 2013 by Dr Ankit Mahadevia in collaboration with the Partners Innovation Fund, Spero Therapeutics is supported by the Atlas Venture seed program. Atlas Venture, SR

This marks Hyundai’s latest move in supporting the scientific community’s efforts to improve cure rates, diminish acute toxicity from treatments and minimize the risk for late effects for

The initiation follows completion of the first treatment cycle in the three patients enrolled in the seventh dose level cohort, in which L-DOS47 therapy was well tolerated as

As part of the deal, DKSH will provide marketing, sales, warehousing, physical distribution, credit management and collection services for BMS in certain markets. DKSH offers a tailor-made, integrated

APIC produces active pharmaceutical ingredients (APIs), intermediates and investigational new drugs, along with fine chemicals and reagents. The new manufacturing facility, located in a Neuland complex in Pashamylaram,

Additionally, the company has earned a $15m milestone payment from Roche related to the initiation of the randomized, double-blind, placebo-controlled, single ascending dose trial. The trial is designed